As the number of cases of infection by the novel coronavirus around the world rises, so are shares of a number of biotech companies with exposure to experimental vaccines (as was the case a few years back during the Ebola crisis). For four such biotech stocks – two of which are up over 250% since the beginning of the year – CLICK HERE.
In response to the spread of the new Chinese coronavirus – including its reaching the U.S. – U.S. stocks initially tumbled before rebounding as investors focused on positive earnings news. With more bad news and fear concerning the virus likely on the way, what will the virus’s impact be on the stock market? Today’s article provides a comprehensive look at the virus’s impact on Chinese stocks, China-exposed retailers, travel and gaming stocks, and biotech stocks – as well as what history suggests is coming next, potential buying opportunities from coronavirus-triggered selloffs and more. CLICK HERE.
“A solid growth play is a name that appears poised to not only grow at an above-average rate but also reward investors handsomely over the long run,” notes the author of today’s article, who proceeds to highlight three “Buy-rated stocks flagged by the analysts for their strong long-term growth narratives. On top of this, each boasts substantial upside potential from the current share price.” For these three stocks – including a biopharmaceutical company focused on underserved patient communities – For more, CLICK HERE.
The author of today’s article acknowledges that “generally speaking you DO NOT want to buy stocks in a bad sector”. So why did he recently buy a highly speculative penny stock in a sector that he admits “has been among the worst performing sectors of the entire stock market in the past twelve months” (i.e. cannabis stocks)? Because he believes the sector is set for a weeks-long (or even months-long) rally and that new companies in the sector – such as the stock in question – are likely to go up the most. For more, CLICK HERE.
“There is a mania going on in the stock market, but not in the terms you would think,” declares the author of today’s article, who further explains that “The mania is not in terms of stock market gains. The mania is in stock market gurus almost unanimously saying that all is clear.” For more on this mania that the author sees taking place and what he believes investors should be watching – including the potential market impact of the deadly coronavirus, which has now reached the U.S. – CLICK HERE.
When it comes to foretelling an impending price move by a stock, one indicator can be unusual options activity. However, the author of today’s article notes that “Using option activity as an indicator of impending price moves is difficult, subjective, and unreliable.” To increase your chances of success when using options activity to predict a price move, the author examines “some basic criteria for identifying meaningful activity and avoiding the chase for an activity that ends up being useless noise.” For more, CLICK HERE.
For a moment, it looked like a dramatic flare-up of tensions between the U.S. and Iran could be the black swan event of 2020, but the situation has since de-escalated (for now). So what other potential surprises might 2020 have in store? The global strategy team at Credit Suisse has devised its annual surprise predictions, and while the author of today’s article notes that, while “the investment bank takes pains to insist this isn’t a set of expectations for the year…the predictions do pose some interesting food for thought.” For more, CLICK HERE.
While Amazon is the king of online retail, the author of today’s article points to an Achilles heel that threatens its crown – and that has Walmart nipping at the online retail behemoth’s heels. What is Amazon’s Achilles heel, what’s Walmart’s master plan to take advantage of it and charge ahead of its rival, and is buying Walmart stock like buying Amazon stock but at a 73% discount? CLICK HERE.
More than 10 years into this bull market, Buy and Outperform analyst ratings generally come with implied upside potential of 8% to 10%. However, the author of today’s article notes that “One area of the market that can see much greater upside opportunities, which also implies a greater risk, is the biotech and emerging pharmaceutical stocks” – and he proceeds to highlight 20 biotech and pharma stocks that have seen analyst calls since January 1st that suggest much larger upside potential. For more, CLICK HERE.
When it comes to exchange-traded funds to consider for the next year, today’s article highlights some ideas as identified by pros in the ETF industry, noting that “Two respondents think that after a strong run, investors might do better to look outside the U.S. for returns. One, perhaps not surprisingly, thinks his own fund is best positioned to grab investor interest in the value trade, now that there seems to be more runway in the business cycle. And another is wondering whether that will prompt investors to become less cautious.” For more, CLICK HERE.